BB
TSRX

BB Biotech’s TRIUS THERAPEUTICS INC COM STK (DE) TSRX Stock Holding History

BB Biotech’s Portfolio TSRX Stock Details TSRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-280,000
Closed -$2.27M – 28
2013
Q2 		$2.27M Buy
+280,000
New +$2.07M 0.16% 22

Other funds holding TSRX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.3B AUM 21.14% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

BB Biotech's TSRX Position: Q3 2013 in Review

BB Biotech sold out of TRIUS THERAPEUTICS INC COM STK (DE) (TSRX) in Q3 2013, closing a stake of 280,000 shares — an estimated $2.27M sold.

BB Biotech first reported a position in TSRX in Q2 2013 and held it in 1 quarter. The position peaked at $2.27M in Q2 2013. 7 funds tracked by Wall St. Rank hold TSRX as of Q3 2013.

  • BB Biotech reported no remaining TRIUS THERAPEUTICS INC COM STK (DE) position as of Q3 2013 after selling out during the quarter.
  • BB Biotech sold 280,000 TRIUS THERAPEUTICS INC COM STK (DE) shares in Q3 2013, an estimated $2.27M.
  • BB Biotech first reported a position in TRIUS THERAPEUTICS INC COM STK (DE) in Q2 2013 and held it in 1 quarter.
  • BB Biotech's TRIUS THERAPEUTICS INC COM STK (DE) position peaked at $2.27M in Q2 2013.
  • 7 funds tracked by Wall St. Rank held TRIUS THERAPEUTICS INC COM STK (DE) as of Q3 2013.

Based on BB Biotech's 13F filing for Q3 2013, filed 12 Nov 2013.